Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice

被引：28
作者：
Christensen B. [1 ,2 ]
Rubin D.T. [1 ]
机构：
[1] University of Chicago Medicine Inflammatory Bowel Disease Center, 5841 S. Maryland Ave., MC4076, Room M410, Chicago, 60637, IL
[2] Department of Gastroenterology, Alfred Hospital and Monash University, Melbourne
来源：
Current Gastroenterology Reports | 2016年 / 18卷 / 1期
关键词：
Colonoscopy; Crohn’s disease; Disease activity indices; Endoscopic disease activity; Inflammatory bowel disease; Mucosal activity; Mucosal healing; Ulcerative colitis;
D O I：
10.1007/s11894-015-0477-6
中图分类号：
学科分类号：
摘要：
Endoscopic assessment of disease activity is an essential part of clinical practice in inflammatory bowel disease (IBD) and is used for diagnosis, prognosis, monitoring for dysplasia and increasingly for the evaluation of mucosal or endoscopic response to therapy. Recently, mucosal or endoscopic healing has emerged as a key goal of therapy as it has been found that patients who achieve endoscopic remission have improved outcomes compared to those who do not, and this may be independent of their clinical disease activity. However, there is currently no validated definition of mucosal healing and there are numerous endoscopic scoring systems proposed to define endoscopic activity and response to therapy in both ulcerative colitis and Crohn’s disease. This article will discuss the most common endoscopic scores used to measure endoscopic disease activity in IBD, the pros and cons of each of these scoring systems and proposed definitions for endoscopic response or remission that exist for each. In addition, the role of endoscopy in prognosticating the disease course is discussed and how endoscopy can be utilized as part of a “treat-to-target” treatment strategy where endoscopy results direct decisions regarding medical strategies in clinical practice is highlighted. © 2016, Springer Science+Business Media New York.
引用
收藏
页码：1 / 11
页数：10
相关论文
共 77 条
  • [1] Colombel J.F., Et al., Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis, Gastroenterology, 141, 4, pp. 1194-1201, (2011)
  • [2] Modigliani R., Et al., Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etude Therapeutique des affections Inflammatoires digestives, Gastroenterology, 98, 4, pp. 811-818, (1990)
  • [3] Rutgeerts P., Et al., Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med, 353, 23, pp. 2462-2476, (2005)
  • [4] Baars J.E., Et al., Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation, Inflamm Bowel Dis, 18, 9, pp. 1634-1640, (2012)
  • [5] Gomes P., Et al., Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease, Gut, 27, 1, pp. 92-95, (1986)
  • [6] Neurath M.F., Travis S.P., Mucosal healing in inflammatory bowel diseases: a systematic review, Gut, 61, 11, pp. 1619-1635, (2012)
  • [7] Sandborn W.J., Et al., Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab, Gastroenterology, 137, 4, pp. 1250-1260, (2009)
  • [8] Froslie K.F., Et al., Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort, Gastroenterology, 133, 2, pp. 412-422, (2007)
  • [9] Feagan B.G., Et al., The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients, Am J Gastroenterol, 102, 4, pp. 794-802, (2007)
  • [10] Meucci G., Et al., Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study, Inflamm Bowel Dis, 18, 6, pp. 1006-1010, (2012)
12345678